(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Inn The executives: A Remunerating Profession Decision for Energetic People- National health ranking puts Georgia near bottom of list. Here's why
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
- Hundreds rally in West Bank against Israeli death penalty for Palestinians
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Supportive Tips On Home loans For First-Time Home Purchasers
